$22.700
-0.763 (-3.36%)收盘时
ELAN 资讯
ELAN 事件
U.S. 10-Year Treasury Yield Falls to Near One-Month Lows
The yield on the U.S. 10-year Treasury note fell on Tuesday, hovering near one-month lows, following weaker housing data while investors also continued to assess persistent inflationary pressures ahead of the Fed's interest rate decision next week. Housing starts fell 5.2% in September, while pending home sales dropped to a record low, reflecting the continued strain of elevated mortgage rates on housing demand. The Fed is widely expected to leave interest rates unchanged next week, while markets anticipate a 25 basis point rate hike in December. Meanwhile, crude oil prices moved lower and stocks turned higher following an unconfirmed report from Qatari newspaper Al-Araby Al-Jadeed that Qatar and Pakistan presented a mediation proposal to address the demands of the U.S. and Iran.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:General Motorsreported better-than-expected Q3 sales and earnings and approved a new $20B share repurchase planGE Aerospace posted a "beat and raise" Q3 reportSalesforceagreed to acquire Brazefor $5.66B in enterprise value, or $47.50 per share in cashByteDance, Alibabaand Tencenthave ordered over 3M NvidiaRTX PRO 5500 graphics cards for over $35B, Reuters reportsIndustrial conglomerate 3Mlifted its annual profit forecast as cost-control initiatives and higher prices support margins2. WALL STREET CALLS:Loop Capital downgraded Appleto Hold on iPhone concernsAkamaiupgraded to Strong Buy at Raymond James following recent pullbackBarclays downgraded NuScale Powerto Underweight on commercial delaysBlackRockupgraded to Buy at TD CowenJefferies downgraded Elancoand Zoetisto Hold3. AROUND THE WEB:NRx Pharmaceuticalsis advancing Ketafree, a preservative-free ketamine formulation, and is seeking FDA approval while arguing that benzethonium chloride, a preservative used in most ketamine products, poses health risks, a claim it has not substantiated with evidence, NY Times saysTelesat'screditors have proposed a C$3.2B deal to help the company pay down a coming debt maturity and avert a default, WSJ reportsAustralia is set to sue Meta'sFacebook, TikTok, as well as other major digital platforms for not complying with the country's social media ban for children under 16, Bloomberg saysAlphabet'sWaymo, which currently operates about 4,000 cars, is looking to use the $5B it has recently borrowed to expand its fleet to 8,000 vehicles by the end of 2026 and grow that number to 20,000 by the end of 2027, Semafor reportsNetflixis overhauling its creative leadership in hopes of getting domestic audiences to watch more of its content, WSJ reports4. MOVERS:Myriad Genetics (MYRD) gains after announcing it will sell its Prenatal Health testing business to LabcorpHertzincreases after announcing Oro Mobility secured an $80M strategic equity investment from a consortium of investorsEquifaxhigher after reporting Q3 results, providing guidance for Q4, and narrowing its outlook for FY26Borr Drillinglower after Fearnley downgraded the stock to HoldBaxterfalls after the FDA issued a warning letter following an inspection of its facility5. EARNINGS/GUIDANCE:RTXreported Q3 results and raised its guidance for FY26Krogerbacked its guidance for FY26Ally Financialreported Q3 results, with EPS and revenue beating consensusValmontreported Q3 results and increased its outlook for FY26, with CEO Avner Applbaum commenting this was "another quarter of sales and earnings growth"Genuine Partsreported Q3 results and narrowed its guidance for FY26INDEXES:Near midday, the Dow was up 513.06, or 0.99%, to 52,479.09, the Nasdaq was up 76.22, or 0.29%, to 26,507.11, and the S&P 500 was up 35.46, or 0.46%, to 7,726.19.
Franklin Electric Appoints Luciana Amaro as Chief Human Resources Officer
Franklin Electric (FELE) announced that Luciana Amaro has been appointed chief human resources officer. Amaro will report to Joe Ruzynski, CEO, and will lead the company's global human resources strategy. Most recently, she served as senior VP of human resources at Elanco (ELAN).
Elanco Animal Health Completes 25,000-SF Manufacturing Expansion
Elanco Animal Health announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space. The company recently announced the phased launch of Befrena, a new anti-IL-31 mAb injection for treatment of canine allergic and atopic dermatitis. In addition to Befrena, Elanco's first mAb product, Trutect, formerly Canine Parvovirus Monoclonal Antibody, received full approval in 2025 as the first and only approved therapeutic solution for canine parvovirus. Both products are currently manufactured at Elanco's Elwood facility. In addition to increasing production capacity of the manufacturing site by more than four times with upstream and downstream processing equipment, this $120M investment also includes: a new pilot plant to accelerate process development and deliver the materials needed for clinical testing, a new quality control laboratory and additional support spaces. Another $30M investment is planned through 2028 to include additional warehousing, for a total investment of $150M. Design-build firm Burns & McDonnell, headquartered in Kansas City, Mo., led the expansion project as the primary provider of integrated design and construction services.
Elanco Receives FDA Emergency Authorization for CLiK Extra to Prevent New World Screwworm Infestations
Elanco announced it has received Emergency Use Authorization from the U.S. Food and Drug Administration for CLiK Extra wound spray for application on or around wounds to prevent infestations of New World screwworm larvae in sheep, cattle, goats, swine and camelids, as well as captive and captured cervids, American bison, bighorn sheep and Sonoran pronghorn. Livestock producers and veterinarians can apply Elanco's CLiK Extra spray on or around wounds, including those associated with birth and following surgical procedures, on animals to help prevent infestations of New World screwworm larvae before they occur. However, if a wound is already infested or an infestation develops after administration, alternative treatment will be necessary since CLiK Extra has not been shown to treat active New World screwworm infestations. Elanco's Negasunt Powder and Tanidil received emergency authorizations for prevention and treatment of New World screwworm earlier this year. These products will be available only through the U.S. Animal Plant Health and Inspection Service and its National Veterinary Stockpile as distributed in coordination with state animal health officials and federally recognized tribal agencies. Elanco also offers producers Catron IV, one of the few EPA registered products labeled for treatment against screwworm in a variety of livestock species. This screwworm and ear tick spray can help producers kill and control screwworm flies and maggots on beef and dairy cattle, sheep, goats, hogs and horses.
Elanco Reports Q2 Revenue of $1.37B, Beating Consensus
Reports Q2 revenue $1.37B, consensus $1.31B. "Elanco's second quarter results demonstrate our momentum and leadership in the attractive animal health industry," stated Jeff Simmons, President and CEO of Elanco. "Organic constant currency revenue growth of 8% was led by U.S. Pet Health and U.S. Farm Animal each up 11%. We saw strong contributions from both price and volume, as consumer demand for our basket of innovation drove market share gains and stabilized our base business. Zenrelia - our newest blockbuster - was the single largest contributor to global Elanco growth, closely followed by Credelio Quattro. As we are raising our top- and bottom-line full-year outlook, including faster than planned margin expansion and net debt deleverage, our consistent delivery demonstrates our Innovation Portfolio Productivity (IPP) strategy is working. We also continue to expect a sustainable mid-single digit CAGR in animal health through the global drivers that matter most in pets and protein. Elanco is well positioned through our differentiated innovation, our comprehensive portfolio, our diverse go-to-market model, and our commercial execution, creating durable value for our customers, our shareholders, and the industry."
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。







